273 related articles for article (PubMed ID: 18685919)
1. Advances in the understanding of the mechanism of action of IVIg.
Hartung HP
J Neurol; 2008 Jul; 255 Suppl 3():3-6. PubMed ID: 18685919
[TBL] [Abstract][Full Text] [Related]
2. Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells.
Issekutz AC; Rowter D; Miescher S; Käsermann F
Clin Immunol; 2015 Oct; 160(2):123-32. PubMed ID: 25982320
[TBL] [Abstract][Full Text] [Related]
3. Role of natural antibodies in immune homeostasis: IVIg perspective.
Vani J; Elluru S; Negi VS; Lacroix-Desmazes S; Kazatchkine MD; Bayry J; Kaveri SV
Autoimmun Rev; 2008 Jun; 7(6):440-4. PubMed ID: 18558359
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin in autoimmune neuromuscular diseases.
Dalakas MC
JAMA; 2004 May; 291(19):2367-75. PubMed ID: 15150209
[TBL] [Abstract][Full Text] [Related]
5. IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies.
Dalakas MC
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34845096
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages.
Andersson J; Skansén-Saphir U; Sparrelid E; Andersson U
Clin Exp Immunol; 1996 May; 104 Suppl 1():10-20. PubMed ID: 8625537
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of action of intravenous immune globulin in immune-mediated diseases.
Mouthon L; Kaveri SV; Spalter SH; Lacroix-Desmazes S; Lefranc C; Desai R; Kazatchkine MD
Clin Exp Immunol; 1996 May; 104 Suppl 1():3-9. PubMed ID: 8625540
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin treatment on anti-GM1 antibodies associated neuropathies inhibits cholera toxin and galectin-1 binding to ganglioside GM1.
Peng W
Immunol Lett; 2012 Apr; 143(2):146-51. PubMed ID: 22289946
[TBL] [Abstract][Full Text] [Related]
9. Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.
Dalakas MC
Neurotherapeutics; 2021 Oct; 18(4):2397-2418. PubMed ID: 34766257
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulation and remyelination: two aspects of human polyclonal immunoglobulin treatment in immune mediated neuropathies?
van Schaik IN; Vermeulen M; Brand A
Mult Scler; 1997 Apr; 3(2):98-104. PubMed ID: 9291162
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production.
Heidt S; Roelen DL; Eijsink C; Eikmans M; Claas FH; Mulder A
Clin Exp Immunol; 2009 Oct; 158(1):99-105. PubMed ID: 19737236
[TBL] [Abstract][Full Text] [Related]
12. Facing the enigma of immunomodulatory effects of intravenous immunoglobulin.
Sapir T; Shoenfeld Y
Clin Rev Allergy Immunol; 2005 Dec; 29(3):185-99. PubMed ID: 16391393
[TBL] [Abstract][Full Text] [Related]
13. B cells are resistant to immunomodulation by 'IVIg-educated' dendritic cells.
Maddur MS; Hegde P; Sharma M; Kaveri SV; Bayry J
Autoimmun Rev; 2011 Dec; 11(2):154-6. PubMed ID: 21864723
[TBL] [Abstract][Full Text] [Related]
14. Exogenous immunoglobulin downregulates T-cell receptor signaling and cytokine production.
Tawfik DS; Cowan KR; Walsh AM; Hamilton WS; Goldman FD
Pediatr Allergy Immunol; 2012 Feb; 23(1):88-95. PubMed ID: 21265884
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the cellular immune system by intravenous immunoglobulin.
Tha-In T; Bayry J; Metselaar HJ; Kaveri SV; Kwekkeboom J
Trends Immunol; 2008 Dec; 29(12):608-15. PubMed ID: 18926775
[TBL] [Abstract][Full Text] [Related]
16. Complement deposition induced by binding of anti-contactin-1 auto-antibodies is modified by immunoglobulins.
Appeltshauser L; Weishaupt A; Sommer C; Doppler K
Exp Neurol; 2017 Jan; 287(Pt 1):84-90. PubMed ID: 27746185
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders.
Larroche C; Chanseaud Y; Garcia de la Pena-Lefebvre P; Mouthon L
BioDrugs; 2002; 16(1):47-55. PubMed ID: 11909001
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells.
Séïté JF; Goutsmedt C; Youinou P; Pers JO; Hillion S
J Allergy Clin Immunol; 2014 Jan; 133(1):181-8.e1-9. PubMed ID: 24139609
[TBL] [Abstract][Full Text] [Related]
19. [Mechanisms of action of intravenous immunoglobulins in the treatment of autoimmune diseases].
Mouthon L; Hurez V; Kazatchkine M
Ann Med Interne (Paris); 1993; 144(8):506-13. PubMed ID: 8179238
[TBL] [Abstract][Full Text] [Related]
20. [Immunomodulatory effects of intravenous immunoglobulins].
Guilpain P; Chanseaud Y; Tamby MC; Larroche C; Guillevin L; Kaveri SV; Kazatchkine MD; Mouthon L
Presse Med; 2004 Oct; 33(17):1183-94. PubMed ID: 15523290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
